Welcome to Francis Academic Press

Frontiers in Medical Science Research, 2021, 3(3); doi: 10.25236/FMSR.2021.030302.

The effect of acarbose on the gut microbiota: an evidence-based review


Xianhe Zheng1, Zhongyun Zhang2, Jiangchuan Xie3

Corresponding Author:
Xianhe Zheng

1Tianjin University of Commerce, 409 Guanrong Road, Beichen District, Tianjin, China

2University of California Santa Barbara, Santa Barbara, California 93106, United States

3Shanghai Yangjing High School, No. 67, Weifang West Road, Pudong New Area, Shanghai, China


Acabose is wildly used in various disease treatments and could interact with the gut flora, while the gut flora plays a significant role in human body. This means that acarbose is able to be utilized to improve the efficacy and patient experience by measuring and regulating intestinal flora to achieve precise medicine intake. Moreover, it is also capable to be employed for treating and preventing more other diseases by targeting the gut flora to open up new uses. Based on this hypothesis, we summarized the reasons, methods and results of the interactions between acarbose and intestinal flora, as well as ways for health promotion according to existing experimental results and literature reviews.


Acarbose, gut microbiota, Bacteria, type-II diabetes

Cite This Paper

Xianhe Zheng, Zhongyun Zhang, Jiangchuan Xie. The effect of acarbose on the gut microbiota: an evidence-based review. Frontiers in Medical Science Research (2021) Vol. 3 Issue 3: 4-11. https://doi.org/10.25236/FMSR.2021.030302.


[1] Wehmeier UF, Piepersberg W. Biotechnology and molecular biology of the alpha-glucosidase inhibitor acarbose. Appl Microbiol Biotechnol. 2004 Feb; 63(6):613-25. doi: 10.1007/s00253-003-1477-2. Epub 2003 Dec 11. PMID: 14669056.

[2] Zhang DQ, Zhu JH, Chen WC. Acarbose: a new option in the treatment of ulcerative colitis by increasing hydrogen production. Afr J Tradit Complement Altern Med. 2012 Oct 1;10(1):166-9. PMID: 24082339; PMCID: PMC3746371.

[3] Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF, Dinan TG. Minireview: Gut microbiota: the neglected endocrine organ. Mol Endocrinol. 2014 Aug;28(8):1221-38. doi: 10.1210/me.2014-1108. Epub 2014 Jun 3. PMID: 24892638; PMCID: PMC5414803.

[4] Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010 Mar 4;464(7285):59-65. doi: 10.1038/nature08821. PMID: 20203603; PMCID: PMC3779803.

[5] Flint HJ, Scott KP, Louis P, Duncan SH. The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol. 2012 Sep 4;9(10):577-89. doi: 10.1038/nrgastro.2012.156. PMID: 22945443.

[6] Gentile CL, Weir TL. The gut microbiota at the intersection of diet and human health. Science. 2018 Nov 16;362(6416):776-780. doi: 10.1126/science.aau5812. PMID: 30442802.

[7] Musso G, Gambino R, Cassader M. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Diabetes Care. 2010 Oct;33(10):2277-84. doi: 10.2337/dc10-0556. PMID: 20876708; PMCID: PMC2945175.

[8] Moreno-Indias I, Cardona F, Tinahones FJ, Queipo-Ortuño MI. Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus. Front Microbiol. 2014 Apr 29;5:190. doi: 10.3389/fmicb.2014.00190. PMID: 24808896; PMCID: PMC4010744.

[9] Menees S, Chey W. The gut microbiome and irritable bowel syndrome. F1000Res. 2018 Jul 9;7: F1000 Faculty Rev-1029. doi: 10.12688/f1000research.14592.1. PMID: 30026921; PMCID: PMC6039952.

[10] Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Fölsch UR, Timmis KN, Schreiber S. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004 May; 53(5):685-93. doi: 10.1136/gut.2003.025403. PMID: 15082587; PMCID: PMC1774050.

[11] Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006 Feb; 55(2):205-11. doi: 10.1136/gut.2005.073817. Epub 2005 Sep 27. PMID: 16188921; PMCID: PMC1856500.

[12] Ho HE, Bunyavanich S. Role of the Microbiome in Food Allergy. Curr Allergy Asthma Rep. 2018 Apr 5; 18(4):27. doi: 10.1007/s11882-018-0780-z. PMID: 29623445.

[13] Sharma S, Tripathi P. Gut microbiome and type 2 diabetes: where we are and where to go? J Nutr Biochem. 2019 Jan; 63:101-108. doi: 10.1016/j.jnutbio.2018.10.003. Epub 2018 Oct 11. PMID: 30366260.

[14] Baba Y, Iwatsuki M, Yoshida N, Watanabe M, Baba H. Review of the gut microbiome and esophageal cancer: Pathogenesis and potential clinical implications. Ann Gastroenterol Surg. 2017 Jun 7; 1(2): 99-104. doi: 10.1002/ags3.12014. PMID: 29863142; PMCID: PMC5881342.

[15] Dahmus JD, Kotler DL, Kastenberg DM, Kistler CA. The gut microbiome and colorectal cancer: a review of bacterial pathogenesis. J Gastrointest Oncol. 2018 Aug; 9(4):769-777. doi: 10.21037/jgo. 2018.04.07. PMID: 30151274; PMCID: PMC6087872.

[16] Fujimura KE, Lynch SV. Microbiota in allergy and asthma and the emerging relationship with the gut microbiome. Cell Host Microbe. 2015 May 13;17(5):592-602. doi: 10.1016/j.chom.2015.04.007. PMID: 25974301; PMCID: PMC4443817.

[17] Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Doré J, Henegar C, Rizkalla S, Clément K. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010 Dec;59(12):3049-57. doi: 10.2337/db10-0253. Epub 2010 Sep 28. PMID: 20876719; PMCID: PMC2992765.

[18] Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012 Oct;143(4):913-6.e7. doi: 10.1053/j.gastro.2012.06.031. Epub 2012 Jun 20. Erratum in: Gastroenterology. 2013 Jan;144(1):250. PMID: 22728514.

[19] Philips CA, Pande A, Shasthry SM, Jamwal KD, Khillan V, Chandel SS, Kumar G, Sharma MK, Maiwall R, Jindal A, Choudhary A, Hussain MS, Sharma S, Sarin SK. Healthy Donor Fecal Microbiota Transplantation in Steroid-Ineligible Severe Alcoholic Hepatitis: A Pilot Study. Clin Gastroenterol Hepatol. 2017 Apr;15(4):600-602. doi: 10.1016/j.cgh.2016.10.029. Epub 2016 Nov 2. PMID: 27816755.

[20] Palleja A, Mikkelsen KH, Forslund SK, Kashani A, Allin KH, Nielsen T, Hansen TH, Liang S, Feng Q, Zhang C, Pyl PT, Coelho LP, Yang H, Wang J, Typas A, Nielsen MF, Nielsen HB, Bork P, Wang J, Vilsbøll T, Hansen T, Knop FK, Arumugam M, Pedersen O. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018 Nov;3(11):1255-1265. doi: 10.1038/s41564-018-0257-9. Epub 2018 Oct 22. PMID: 30349083.

[21] Chen D, Wu J, Jin D, Wang B, Cao H. Fecal microbiota transplantation in cancer management: Current status and perspectives. Int J Cancer. 2019 Oct 15;145(8):2021-2031. doi: 10.1002/ijc.32003. Epub 2018 Dec 30. PMID: 30458058; PMCID: PMC6767494.

[22] Bastiaanssen TFS, Cowan CSM, Claesson MJ, Dinan TG, Cryan JF. Making Sense of … the Microbiome in Psychiatry. Int J Neuropsychopharmacol. 2019 Jan 1;22(1):37-52. doi: 10.1093/ijnp/ pyy067. PMID: 30099552; PMCID: PMC6313131.

[23] Kraeuter AK, Phillips R, Sarnyai Z. The Gut Microbiome in Psychosis From Mice to Men: A Systematic Review of Preclinical and Clinical Studies. Front Psychiatry. 2020 Aug 11;11:799. doi: 10.3389/fpsyt.2020.00799. PMID: 32903683; PMCID: PMC7438757.

[24] Chen Ling, et al. "Research progress on the effect of hypoglycemic drugs on intestinal flora." Chinese Journal of diabetes 28.02(2020):150-152. doi: 10. 3969/j. issn. 1006-6187. 2020. 02. 015

[25] Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016 Jun 2;165(6):1332-1345. doi: 10.1016/j.cell.2016.05.041. PMID: 27259147.

[26] Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008 Jan 15;27(2):104-19. doi: 10.1111/j.1365-2036.2007.03562.x. Epub 2007 Oct 25. PMID: 17973645.

[27] Mathewson ND, Jenq R, Mathew AV, Koenigsknecht M, Hanash A, Toubai T, Oravecz-Wilson K, Wu SR, Sun Y, Rossi C, Fujiwara H, Byun J, Shono Y, Lindemans C, Calafiore M, Schmidt TM, Honda K, Young VB, Pennathur S, van den Brink M, Reddy P. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol. 2016 May;17(5):505-513. doi: 10.1038/ni.3400. Epub 2016 Mar 21. Erratum in: Nat Immunol. 2016 Sep 20;17 (10 ):1235. PMID: 26998764; PMCID: PMC4836986.

[28] Zhang X, Fang Z, Zhang C, Xia H, Jie Z, Han X, Chen Y, Ji L. Effects of Acarbose on the Gut Microbiota of Prediabetic Patients: A Randomized, Double-blind, Controlled Crossover Trial. Diabetes Ther. 2017 Apr;8(2):293-307. doi: 10.1007/s13300-017-0226-y. Epub 2017 Jan 27. PMID: 28130771; PMCID: PMC5380489.

[29] Gu Y, Wang X, Li J, Zhang Y, Zhong H, Liu R, Zhang D, Feng Q, Xie X, Hong J, Ren H, Liu W, Ma J, Su Q, Zhang H, Yang J, Wang X, Zhao X, Gu W, Bi Y, Peng Y, Xu X, Xia H, Li F, Xu X, Yang H, Xu G, Madsen L, Kristiansen K, Ning G, Wang W. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nat Commun. 2017 Nov 27;8(1):1785. doi: 10.1038/s41467-017-01682-2. PMID: 29176714; PMCID: PMC5702614.

[30] Baxter NT, Lesniak NA, Sinani H, Schloss PD, Koropatkin NM. The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome. mSphere. 2019 Feb 6;4(1):e00528-18. doi: 10.1128/mSphere.00528-18. Erratum in: mSphere. 2019 May 22;4(3): PMID: 30728281; PMCID: PMC6365613.

[31] Zhang X, Fang Z, Zhang C, et al. Effects of acarbose on the gut microbiota of prediabetic patients: a randomized, double -blind, controlled crossover trial. Diabetes Ther, 2017, 8: 293-307.

[32] Su B, Liu H, Li J, Sunli Y, Liu B, Liu D, Zhang P, Meng X. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus. J Diabetes. 2015 Sep;7(5):729-39. doi: 10.1111/1753-0407.12232. Epub 2015 Jan 15. PMID: 25327485.

[33] Akour A, Kasabri V, Bulatova N, et al. Association of oxytocin with glucose intolerance and inflammation biomarkers in metabol- ic syndrome patients with and without prediabetes. Rev Diabet Stud, 2018, 14: 364-371.

[34] Gu Y, Wang X, Li J, et al. Analyses of gut microbiota and plas- ma bile acids enable stratification of patients for antidiabetic treat- ment. Nat Commun, 2017, 8: 1785.

[35] Maruhama Y, Nagasaki A, Kanazawa Y, Hirakawa H, Goto Y, Nishiyama H, Kishimoto Y, Shimoyama T. Effects of a glucoside-hydrolase inhibitor (Bay g 5421) on serum lipids, lipoproteins and bile acids, fecal fat and bacterial flora, and intestinal gas production in hyperlipidemic patients. Tohoku J Exp Med. 1980 Dec;132(4):453-62. doi: 10.1620/tjem.132.453. PMID: 7256727.

[36] Liu Xiaocui, Hu Yugang, Chen Weizhong, Effect of acarbose on intestinal flora in patients with diabetes mellitus, doi: 10.3969/j.i ss n. 1004-5775.2017. 06.029

[37] Zhang M, Feng R, Yang M, Qian C, Wang Z, Liu W, Ma J. Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats. BMJ Open Diabetes Res Care. 2019 Sep 20; 7(1): e000717. doi: 10.1136/bmjdrc-2019-000717. PMID: 31641523; PMCID: PMC6777410.

[38] Fernandes J, Su W, Rahat-Rozenbloom S, Wolever TM, Comelli EM. Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. Nutr Diabetes. 2014 Jun 30;4(6):e121. doi: 10.1038/nutd.2014.23. PMID: 24979150; PMCID: PMC4079931.

[39] Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH, Jakobsen M. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010 Feb 5;5(2):e9085. doi: 10.1371/journal.pone.0009085. PMID: 20140211; PMCID: PMC2816710.

[40] Zhou W, Xu H, Zhan L, Lu X, Zhang L. Dynamic Development of Fecal Microbiome During the Progression of Diabetes Mellitus in Zucker Diabetic Fatty Rats. Front Microbiol. 2019 Feb 14;10:232. doi: 10.3389/fmicb.2019.00232. PMID: 30837966; PMCID: PMC6382700.

[41] Duncan SH, Belenguer A, Holtrop G, Johnstone AM, Flint HJ, Lobley GE. Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl Environ Microbiol. 2007 Feb;73(4):1073-8. doi: 10.1128/AEM.02340-06. Epub 2006 Dec 22. PMID: 17189447; PMCID: PMC1828662.

[42] Tan K, Tesar C, Wilton R, Jedrzejczak RP, Joachimiak A. Interaction of antidiabetic α-glucosidase inhibitors and gut bacteria α-glucosidase. Protein Sci. 2018 Aug; 27(8): 1498-1508. doi: 10.1002/ pro.3444. Epub 2018 Jul 10. PMID: 29761590; PMCID: PMC6153411.

[43] Sivaprakasam S, Prasad PD, Singh N. Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis. Pharmacol Ther. 2016 Aug; 164: 144-51. doi: 10.1016/j.pharmthera. 2016.04.007. Epub 2016 Apr 23. PMID: 27113407; PMCID: PMC4942363.

[44] Rosak C, Mertes G. Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations. Diabetes Metab Syndr Obes. 2012; 5: 357-67. doi: 10.2147/DMSO.S28340. Epub 2012 Oct 12. PMID: 23093911; PMCID: PMC3476372.

[45] Suzuki Y, Sano M, Hayashida K, Ohsawa I, Ohta S, Fukuda K. Are the effects of alpha-glucosidase inhibitors on cardiovascular events related to elevated levels of hydrogen gas in the gastrointestinal tract? FEBS Lett. 2009 Jul 7;583(13):2157-9. doi: 10.1016/j.febslet.2009.05.052. Epub 2009 Jun 6. PMID: 19505462.

[46] Gentile S, Guarino G, Romano M, Alagia IA, Fierro M, Annunziata S, Magliano PL, Gravina AG, Torella R. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol. 2005 Feb;3(2):184-91. doi: 10.1016/s1542-3565(04)00667-6. PMID: 15704053.

[47] Vaziri ND, Zhao YY, Pahl MV. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant. 2016 May;31(5):737-46. doi: 10.1093/ndt/gfv095. Epub 2015 Apr 16. PMID: 25883197.

[48] Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y. Acarbose treatment lowers generation and serum concentrations of the protein-bound solute p-cresol: a pilot study. Kidney Int. 2006 Jul;70(1):192-8. doi: 10.1038/sj.ki.5001523. Epub 2006 May 10. PMID: 16688114.

[49] McIntyre A, Gibson PR, Young GP. Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut. 1993 Mar;34(3):386-91. doi: 10.1136/gut.34.3.386. PMID: 8386131; PMCID: PMC1374147.

[50] Segain JP, Raingeard de la Blétière D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottière HM, Galmiche JP. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut. 2000 Sep;47(3):397-403. doi: 10.1136/gut.47.3.397. PMID: 10940278; PMCID: PMC1728045. 

[51] Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, Brown D, Stares MD, Scott P, Bergerat A, Louis P, McIntosh F, Johnstone AM, Lobley GE, Parkhill J, Flint HJ. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011 Feb;5(2):220-30. doi: 10.1038/ismej.2010.118. Epub 2010 Aug 5. PMID: 20686513; PMCID: PMC3105703.

[52] Wolever TM, Chiasson JL. Acarbose raises serum butyrate in human subjects with impaired glucose tolerance. Br J Nutr. 2000 Jul;84(1):57-61. PMID: 10961161.

[53] Weaver GA, Tangel CT, Krause JA, Parfitt MM, Jenkins PL, Rader JM, Lewis BA, Miller TL, Wolin MJ. Acarbose enhances human colonic butyrate production. J Nutr. 1997 May;127(5):717-23. doi: 10.1093/jn/127.5.717. PMID: 9164992.

[54] Greenway F, Wang S, Heiman M. A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report. Benef Microbes. 2014 Mar;5(1):29-32. doi: 10.3920/BM2012.0063. PMID: 23685372. 

[55] Yu MH, Lin MC, Huang CN, Chan KC, Wang CJ. Acarbose inhibits the proliferation and migration of vascular smooth muscle cells via targeting Ras signaling. Vascul Pharmacol. 2018 Apr;103-105:8-15. doi: 10.1016/j.vph.2018.02.001. Epub 2018 Feb 9. PMID: 29432898.

[56] Hanefeld M, Schaper F. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther. 2008 Feb;6(2):153-63. doi: 10.1586/14779072.6.2.153. Erratum in: Expert Rev Cardiovasc Ther. 2009 Mar;7(3):330. PMID: 18248270.

[57] Standl E, Theodorakis MJ, Erbach M, Schnell O, Tuomilehto J. On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol. 2014 Apr 16;13:81. doi: 10.1186/1475-2840-13-81. PMID: 24742256; PMCID: PMC3996310.

[58] Yan WW, Chen GH, Wang F, Tong JJ, Tao F. Long-term acarbose administration alleviating the impairment of spatial learning and memory in the SAMP8 mice was associated with alleviated reduction of insulin system and acetylated H4K8. Brain Res. 2015 Apr 7; 1603: 22-31. doi: 10.1016/j.brainres. 2015.01.042. Epub 2015 Jan 31. PMID: 25645154.

[59] Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004 Jan; 25(1): 10-6. doi: 10.1016/s0195-668x(03)00468-8. PMID: 14683737.

[60] Hanefeld M. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol. 2007 Aug 15; 6: 20. doi: 10.1186/1475-2840-6-20. PMID: 17697384; PMCID: PMC2040135.